



Governor's Office of Economic Development

Centers of Excellence

Funding Recipients for the 2009-10 Centers of Excellence Program

**Total Proposals – 28 Submitted – 13 Awarded Funding:
12 Second Year Submissions– 8 Awarded funding
16 First Year Submissions - 5 Awarded funding**

**BYU – 4 Awarded Funding (9 Submitted)
USU – 1 Awarded Funding (2 Submitted)
UU – 8 Awarded Funding (16 Submitted)
CEU – 0 Awarded Funding (1 Submitted)**

**8 Second Year Proposals Awarded Funding
5 First Year (New) Proposals Awarded Funding**

Licensee / (Center -University)

<u>CEO or Principal</u>	<u>Years Funded to Date</u>	<u>Award Amount</u>
-------------------------	-----------------------------	---------------------

COSMAS, Inc. (Center for Nanoparticle Production - BYU)		
Lynn Astle, CEO	2nd Year	\$200,000

Cosmas, Inc. is involved in the development of a novel process for making nanoparticles which have a strong competitive advantage for the production of gamma-alumina supported platinum and palladium catalysts, the largest sector of the supported catalyst market.

GlycoMira, Inc. (SAGE - U/U)		
Tim Miller, CEO	2nd Year	\$325,000

Glycomira is developing a new class of anti-inflammatory compounds and will be targeting skin diseases like rosacea and eczema followed by systemic diseases like osteo-arthritis and diabetic retinopathy.

Heavystone Laboratory, LLC (Center for Functionally Graded and Designed Cemented Tungsten Carbide and Polycrystalline Diamond Composite Materials - U/U)		
Dr. Al Poskanzer, CEO	2nd Year	\$ 140,000

Heavystone Laboratory have developed an innovative process and products of functionally graded cemented tungsten carbide material for manufacturing industrial applications including metalworking, oil and gas drilling, geothermal energy exploration, mining, construction, high-wear components, and many other industrial applications that requires extreme wear resistance and impact resistance.



Governor's Office of Economic Development

Centers of Excellence

iVeena, LLC. (Moran Eye Center- UU)

Dr. Balamurali Ambati, Pres and CMO; Greg Jones, Acting CEO

New

\$100,000

iVeena, LLC, is an early-stage biotechnology company with the mission of developing a novel proprietary drug delivery device, called the Capsule Drug Delivery Ring, for treatment of the leading blinding diseases. iVeena will fundamentally change the way eye diseases are treated and improve the quality of life of more than 1 million people/year in the United States and potentially 3 million/year worldwide by preserving their vision and simplifying treatment.

JSK Therapeutics, Inc (Division of Medical Oncology – UU)

Dr. Paul J. Shami, CMO

New

\$100,000

The main focus of JSK Therapeutics (JSKT) is to develop novel anti- cancer drugs using a new cellular mechanism to inhibit the growth of malignant cells. This mechanism, called glutathionylation, involves triggering a chemical reaction between a naturally occurring molecule (glutathione) and cellular proteins. As a result, proteins that are key to cancer cell growth are inhibited, leading to death of the cancer cells. The scientific founders of JSKT have developed two different strategies to induced glutathionylation.

NanoInjection Technologies, LLC (Center for Compliant Mechanisms – BYU)

Gary Crocker, CEO

New

\$100,000

NanoInjection Technologies LLC has the ability to restructure the rapidly growing biotech marketplace for the injection of DNA and RNA into targeted eggs and other cells with the commercial introduction of the first cellular nanoinjector that both reduces costs and yields a faster DNA implant with significantly higher post injection cell survival rates.

NeuroAdjuvants, Inc. (Dept of Pharmacology and Dept of Med. Chem. – UU)

Dr. Theodore Stanley, CEO

2nd Year

\$300,000

NeuroAdjuvants develops stable, blood-brain-barrier permeable neuropeptide-based compounds for the treatment of nervous system disorders. The initial focus of the Company is to bring new therapies for pain and epilepsy. Pain and epilepsy are both multibillion dollar markets dominated by small molecule therapies with considerable safety concerns and/or suboptimal efficacy in many patient populations. NeuroAdjuvants aspires to address these large unmet medical needs by developing safe, efficacious therapies with novel modes of action.



Governor's Office of Economic Development

Centers of Excellence

Sera Prognostics, Inc. (Joint: BYU Chem/Bio; U/U Dept of OB/GYN)
Dennis Farrar, CEO **2nd Year** **\$300,000**

Sera Prognostics is using a novel serum proteomics technology to identify and commercialize biomarkers from blood samples of pregnant women to predict those at risk for preterm birth, preeclampsia and other pregnancy complications.

Sparkle Cream, LLC. (Food Services Dept. – BYU)
Joel Clark, CEO **New** **\$100,000**

Sparkle Cream's licensed, patented technology allows customers, such as frozen ice cream or frozen yogurt vendors, to carbonate soft serve products such as ice cream and frozen yogurt. The resulting product "sparkles" in the mouth resulting in a fun and novel taste experience.

Thermal Management Technologies, LLC. (Center for Thermal Management Technologies -USU)
Forrest Fackrell, CEO **2nd Year** **\$95,000**

Following two years as a USU Center of Excellence, TMT is a 2008 start-up licensee poised to commercialize innovative thermal management solutions for a variety of markets including aerospace, IT infrastructure, and electric hybrid vehicles.

Thermimage, Inc. (Department of Surgery, Section of Pediatric Urology– U/U)
Douglas Turnquist, CEO **2nd Year** **\$300,000**

Thermimage, Inc. is commercializing a non-invasive medical device technology that will replace the traumatic procedures currently used to detect pediatric Vesicoureteral Reflux (VUR), the effect of which will decrease the number of kidney infections and decrease the risk of permanent kidney damage in over 4 million children every year.

Wastewater Compliance Systems, Inc. (Center for Water Treatment Technology -U/U)
Fred Jaeger, CEO **2nd Year** **\$300,000**

WCS, Inc provides proprietary products and services to enable wastewater lagoon operators to cost-effectively remain in regulatory compliance, to increase lagoon efficiency and capacity, and to avoid substantial capital costs by extending useful life of existing facilities. The solution is called the "poo gloo" and is simple to install and maintain.



Governor's Office of Economic Development

Centers of Excellence

ViroPan, Inc. (Dept of Bioengineering, Microbicide Delivery Lab - U/U)

Dr. Tyler McCabe, CEO

New

\$100,000

ViroPan, Inc. is a company focused on women's health and the prevention of specific viral sexually transmitted infections (STIs) and together with the University of Utah, ViroPan is developing an important proprietary intravaginal ring (IVR) product that is self-inserted by the woman to release, for up to one month, a potent anti-Human Papillomavirus (HPV) agent for the prevention of cervical cancer and genital condylomas (warts).